LPL Financial’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

LPL Financial’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8,573	Closed	-$91.9K	–	5082
2023 Q4	$91.9K	Hold	8,573	–	–	﹤0.01%	4567
2023 Q3	$51.4K	Hold	8,573	–	–	﹤0.01%	4519
2023 Q2	$59.2K	Hold	8,573	–	–	﹤0.01%	4405
2023 Q1	$135K	Buy	8,573 +1,850	+28%	+$36.4K	﹤0.01%	4148
2022 Q4	$134K	Hold	6,723	–	–	﹤0.01%	4091
2022 Q3	$120K	Buy	6,723 +3,850	+134%	+$82.6K	﹤0.01%	4073
2022 Q2	$64K	Hold	2,873	–	–	﹤0.01%	4202
2022 Q1	$80K	Buy	2,873 +350	+14%	+$12.7K	﹤0.01%	4012
2021 Q4	$115K	Buy	+2,523	New	+$170K	﹤0.01%	4118
2016 Q2	–	Sell	-11	Closed	-$9K	–	3038
2016 Q1	$9K	Hold	11	–	–	﹤0.01%	3082
2015 Q4	$11K	Sell	11 -2	-15%	-$2.64K	﹤0.01%	3133
2015 Q3	$15K	Hold	13	–	–	﹤0.01%	2761
2015 Q2	$26K	Buy	13 +4	+44%	+$5.68K	﹤0.01%	2835
2015 Q1	$9K	Hold	9	–	–	﹤0.01%	2769
2014 Q4	$9K	Hold	9	–	–	﹤0.01%	2708
2014 Q3	$9K	Hold	9	–	–	﹤0.01%	2687
2014 Q2	$18K	Buy	+9	New	+$17.8K	﹤0.01%	2659

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial's ONCT Position: Q1 2024 in Review

LPL Financial sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2024, closing a stake of 8,573 shares — an estimated $91.9K sold.

LPL Financial first reported a position in ONCT in Q2 2014 and held it in 17 quarters. The position peaked at $135K in Q1 2023. 24 funds tracked by Wall St. Rank hold ONCT as of Q1 2024.

LPL Financial reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
LPL Financial sold 8,573 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $91.9K.
LPL Financial first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2014 and held it in 17 quarters.
LPL Financial's Oncternal Therapeutics, Inc. Common Stock position peaked at $135K in Q1 2023.
24 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2024.

Based on LPL Financial's 13F filing for Q1 2024, filed 10 May 2024.